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Introduction
Arsenic (As) is regarded as one of the most 
toxic naturally occurring carcinogenic 
metalloids (Chen et al. 1985; Hajji et al. 
2010). Arsenic-containing substances can be 
broadly classified into two groups, organic 
and inorganic arsenicals, with the latter being 
considered to be more toxic to human health. 
Inorganic species such as arsenite (AsIII) and 
arsenate (AsV) are ingested primarily through 
contaminated drinking water and can lead 
to negative health outcomes (Grund et al. 
2008). The acute dose for arsenic poisoning 
(0.17–0.87 mg/kg body weight) can result 
in diarrhea and vomiting as well as kidney 
and liver toxicity (Yu et al. 2006). Long-term 
exposure to arsenic can lead to severe detri-
mental health outcomes including cardio-
vascular disease and malignancies of the 
skin, lung, and bladder (Kapaj et al. 2006; 
Nelson et al. 2006). Although epidemiologi cal 
studies have extensively charac terized the 
association between chronic arsenic exposure 
and the rising incidence of malignant-based 
mortality, a mechanistic understanding of 
arsenic-induced carcinogenicity remains to 
be established (Kurttio et al. 1999). Proposed 
mechanisms include the generation of reactive 
oxygen species, cytotoxicity due to the forma-
tion of a reactive metabolite, inhibition of 
DNA repair, chromo somal aberrations, 
uncontrolled cellular proliferation, and altered 
DNA methyla tion patterns (Shi et al. 2004).
A mounting body of evidence suggests 
that epigenetic mechanisms may play a role 
in the carcino genicity of arsenic, not only 
through aberrant DNA methylation but also 
through altered expression of microRNAs 
and changes in histone modifications (Ren 
et al. 2011). Alterations in DNA methylation 
in response to arsenic exposure is relatively 
well documented, from the identification 
of arsenic as a repressor of DNA methyl-
transferase expression, to the detection of 
a number of hypo- and hyper methylated 
tumor-suppressor and oncogenic promoter 
loci such as p15, p16, p53, Hras1, Myc, and 
Esr1 (Chanda 2006; Reichard and Puga 
2010). Increased global DNA methyla-
tion of peripheral blood mono nuclear cells 
has also been observed and correlated with 
water, urinary, and blood arsenic levels in 
Bangladeshi adults (Niedzwiecki et al. 2013). 
Beyond DNA methylation, little is known 
about the effects arsenic has on the higher-
order chromatin structure. An increasing 
body of evidence suggests that post-
translational histone modifications, particu-
larly histone acetylation, can influence overall 
chromatin structure and gene transcription, 
with clear functional consequences in cellular 
processes such as prolifera tion and apoptosis 
(Füllgrabe et al. 2010). Suitably, alterations 
of histone modification as a result of arsenic 
exposure have been identified, particularly 
changes in phosphorylation, methylation, and 
acetylation; however, relating such modifi-
cations to a mechanistic outcome has been 
limited (Jo et al. 2009; Li et al. 2002; Zhou 
et al. 2008).
Arsenic exposure has been shown to 
increase global histone acetylation via the 
inhibition of histone deacetylases (HDACs) 
at an intensity comparable to the HDAC 
inhibitor triochostatin A (Iacobuzio-Donahue 
2009). Two functionally antagonistic 
enzyme groups mediate histone acetylation, 
comprising three major families of histone 
acetyl transferases (HATs) and four classes of 
HDACs. Because of the opposing functional 
nature of the HDACs and HATs, Peserico 
and Simone (2011) suggested that the relative 
balance, either through expression or activity, 
alters the physiology of cells and provides 
an insight into the pathological outcomes 
in a number of diseases, including cancer. 
This equilibrium needs further study in the 
context of arsenic exposure.
Although multiple arsenic species have 
been used in carcinogenesis studies, the use 
of low-dose arsenic trioxide (As2O3) exposure 
has proven to be suitable in studies pertinent 
to cellular transformation and epigenetic 
aberrations. Low-dose (0.01–1 μM) As2O3 
exposure for 24 hr has been shown to increase 
Address correspondence to N. Hajji, Imperial 
College London, Centre for Pharmacology and 
Therapeutics, Department of Medicine, Du Cane 
Rd., London, W12 0NN, United Kingdom. 
Telephone: 44 (0) 207 594 7394. E-mail: n.hajji@
imperial.ac.uk
Supplemental Material is available online (http://
dx.doi.org/10.1289/ehp.1408302).
This work was supported by a studentship from 
the MRC-PHE Centre for Environmental and 
Health and a MRC Centenary Award to S.R. at 
Imperial College London. 
The authors declare they have no actual or potential 
competing financial interests.
Received: 20 February 2014; Accepted: 6 January 
2015; Advance Publication: 9 January 2015; Final 
Publication: 1 May 2015.
E2F1-Mediated FOS Induction in Arsenic Trioxide–Induced Cellular 
Transformation: Effects of Global H3K9 Hypoacetylation and 
Promoter-Specific Hyperacetylation in Vitro
Sunniyat Rahman,1 Zjwan Housein,1 Aleksandra Dabrowska,1 Maria Dolores Mayán,2 Alan R. Boobis,1 and Nabil Hajji1
1Centre for Pharmacology and Therapeutics, Department of Medicine, Imperial College London, London, United Kingdom; 
2Osteoarticular and Aging Research Group, Rheumatology Division, INIBIC-Hospital Universitario, Coruña, Spain
Background: Aberrant histone acetylation has been observed in carcinogenesis and cellular 
transformation associated with arsenic exposure; however, the molecular mechanisms and cellular 
outcomes of such changes are poorly understood.
oBjective: We investigated the impact of tolerated and toxic arsenic trioxide (As2O3) exposure in 
human embryonic kidney (HEK293T) and urothelial (UROtsa) cells to characterize the alterations 
in histone acetylation and gene expression as well as the implications for cellular transformation.
Methods: Tolerated and toxic exposures of As2O3 were identified by measurement of cell death, 
mitochondrial function, cellular proliferation, and anchorage-independent growth. Histone 
extraction, the MNase sensitivity assay, and immunoblotting were used to assess global histone 
acetylation levels, and gene promoter-specific interactions were measured by chromatin immuno-
precipitation followed by reverse-transcriptase polymerase chain reaction.
results: Tolerated and toxic dosages, respectively, were defined as 0.5 μM and 2.5 μM As2O3 in 
HEK293T cells and 1 μM and 5 μM As2O3 in UROtsa cells. Global hypo acetylation of H3K9 at 
72 hr was observed in UROtsa cells following tolerated and toxic exposure. In both cell lines, toler-
ated exposure alone led to H3K9 hyper acetylation and E2F1 binding at the FOS promoter, which 
remained elevated after 72 hr, contrary to global H3K9 hypo acetylation. Thus, promoter-specific 
H3K9 acetylation is a better predictor of cellular transformation than are global histone acetylation 
patterns. Tolerated exposure resulted in an increased expression of the proto-oncogenes FOS and 
JUN in both cell lines at 72 hr.
conclusion: Global H3K9 hypo acetylation and promoter-specific hyper acetylation facilitate 
E2F1-mediated FOS induction in As2O3-induced cellular transformation.
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proliferation and cell cycle progression in 
normal breast epithelial cells (MCF10A) 
via the elevated expression of CDC6 and 
cyclin D1 (Liu et al. 2010). Kim et al. (2012) 
reported that exposure of BALB/c 3T3 cells 
to tolerated doses of As2O3 led to not only 
cellular transformation and tumor generation 
in nude mice but also to a time-dependent 
increase in H3K27 trimethyla tion mediated 
by the polycomb proteins BM1 and SUZ12. 
Exposure of lung epithelial BEAS-2B cells to a 
tolerated dose of As2O3 resulted in an increase 
in cellular proliferation and the differential 
expression of genes regulating histone H1, 
H3, and H4, as determined by an in silico 
pathway analysis (Stueckle et al. 2012). 
Additional research is required to investi-
gate the carcino genic mecha nisms of As2O3, 
because human exposure to this species of 
arsenic is not limited to tolerated environ-
mental exposures, but also can occur through 
cytotoxic anti cancer therapies (Soignet et al. 
1998). Thus, comparisons between toler-
ated and toxic exposures of As2O3 require 
further examination.
In this study we characterized the toler-
ated and toxic profile of As2O3 exposure 
by analyzing multiple cellular survival 
parameters. We defined a tolerated exposure 
as one that induced significant biological 
effects without causing toxicity, and a toxic 
exposure as one that induced significant 
biological effects leading to toxicity and cell 
death. Identification of a tolerated concentra-
tion ensured epigenetic characterization of the 
relevant cellular context, that is, continued 
proliferation and cellular tolerance rather than 
toxicity. We also charac terized the higher-
order chromatin conformation and histone 
acetylation changes that occur after exposure 
to As2O3 at tolerated and toxic dosages and 
those that occur between early and more 
prolonged exposure. We explored the impact 
of As2O3 exposure on HDAC and HAT 
expression and determined whether specific 
alterations in histone acetylation impinge on 
known proto-oncogenic promoters, altering 
gene expression and leading to increased 
proliferation and carcinogenic potential.
Materials and Methods
Cell culture. Human embryonic kidney 
(HEK) 293T cells and human urothelial 
(UROtsa) cells were generously donated by 
Bertrand Joseph (Karolinska Institutet) and 
Scott Garrett (University of North Dakota), 
respectively. Cells were grown in T75 flasks 
(Sarstedt) with complete medium [Dulbecco’s 
modified Eagle’s medium (DMEM; Sigma) 
completed with 10% fetal bovine serum 
(Sigma), 1% l-glutamine (Gibco), and 1% 
penicillin–streptomycin solution (Sigma)]. 
All cells were cultured at 37°C in a humid 5% 
CO2 atmosphere.
Two-step quantitative real-time reverse-
transcriptase polymerase chain reaction 
(qRT-PCR). Total RNA was extracted using 
the RNeasy Mini Kit (Qiagen) according to 
the manufacturer’s protocol. For two-step 
qRT-PCR, we first synthesized cDNA 
using the ThermoScript RT-PCR System 
(Invitrogen) with a 5-μg input RNA amount 
for each sample. qRT-PCR was then carried 
out on an ABI7500 Fast Real-Time PCR 
System (Applied Biosystems) with a Platinum 
SYBR Green qPCR SuperMix-UDG 
(Invitrogen) used according to the manu-
facturer’s protocol. For quantification, we 
used the standard curve method described 
in detail by Bookout et al. (2006). The 
primers used are provided in Supplemental 
Material, Table S1. 
Clonogenic assay. For the clonogenic 
assay, HEK293T cells were seeded into 
six-well dishes at 500 cells/well and incubated 
overnight in complete medium. The next 
day the medium was changed and the As2O3 
was added (concentrations of 0.5–2.5 μM), 
with no further changes of medium or 
replenishment. After the exposure period, 
cells were washed with phosphate-buffered 
saline (PBS) and fixed in 100% methanol for 
10 min at –20°C. Colonies were stained with 
a solution of 5% Giemsa, 25% methanol, 
and 70% PBS and then counted. The clono-
genic assay has been described in detail (Hajji 
et al. 2010).
Proliferation assay. To examine prolifera-
tion, cells were seeded into 96-well plates at 
4 × 103 cells/well and incubated overnight 
in 100 μL of complete DMEM. Cells were 
then incubated for 72 hr with As2O3 in 
100 μL complete DMEM at final concen-
trations of 0.5 and 2.5 μM. After treatment, 
10 μL of Cell Proliferation Reagent WST-1 
(Roche) was added to each well and the 
plates were incubated for 4 hr at 37°C and 
5% CO2. Medium was homogenized on a 
plate shaker for 1 min, and absorbance was 
then measured at 440 nm in a plate spec-
trophotometer (FLUOstar OPTIMA; 
BMG Labtech). Absorbance readings were 
subtracted from a background measurement 
at 440 nm, which is the absorbance of culture 
medium with WST-1 in the absence of cells. 
Data are presented as a prolifera tive index in 
arbitrary units.
Anchorage-independent growth. Soft 
agar plates were prepared using two agar 
densities. The base layer contained 0.8% 
Noble Agar (Sigma) dissolved in H2O and 
supplemented with DMEM (Sigma) at 
a 1:1 ratio. Cells pre treated with As2O3 as 
described above were plated at a density of 
2.5 × 103 in a 0.4% Noble Agar top layer, 
and supplemented DMEM was replenished 
every 3 days. After 14 days, plates were stained 
with 0.005% Crystal Violet (Sigma) and 20% 
methanol (Sigma) diluted in 1× PBS (Gibco) 
for 2 hr. Colonies were examined under 
a stereo microscope. Details regarding this 
method have been described by Raptis and 
Vultur (2001).
Histone extraction. For histone extraction, 
cells were disrupted on ice in a lysis buffer 
(10 mM Tris, pH 6.5, 50 mM sodium 
bisulphate, 10 mM magnesium chloride, 
8.6% sucrose, 1% Triton X-100). Samples 
were centrifuged at 10,000 × g for 10 min 
at 4°C. Pellets were then washed in ice-cold 
Tris-EDTA (10 mM Tris, pH 7.4, 13 mM 
EDTA) and centrifuged. Histones were 
precipitated by acid extraction as previously 
described (Hajji et al. 2010).
Western blots. We detected acetylation 
of core histones and relative levels of intra-
cellular cellular survival components by 
immunoblotting. We used the following 
antibodies: for histone acetylation analysis: 
anti-acetyl histone H3-Lys 9 (H3K9), anti-
acetyl histone H4-Lys 12, and anti-acetyl 
histone H4-Lys 16 (all from Millipore); for 
intracellular protein analysis: anti-PARP, 
MDM2 (mouse double minute 2 homolog), 
p53 phosphorylated serine 15, p53, BID, 
caspase-3, and β-actin (all from Cell Signaling 
Technology). Cell lysates were separated by 
SDS-PAGE under reducing conditions and 
transferred to a nitrocellulose membrane (GE 
Life Science). Membranes were visualized 
using enhanced chemiluminescence (ECL) 
reagents and exposure to ECL hyperfilm 
(GE Healthcare). Blots were quantified by 
densitometric analysis using ImageJ software 
(National Institutes of Health; http://rsb.info.
nih.gov/ij/), with data normalized against 
β-actin and total histone proteins to correct 
for loading. Antibodies used are listed in 
Supplemental Material, “Antibodies.”
Protein extraction. Total protein extraction 
was achieved by disrupting harvested cells 
with TGN buffer [1 M Tris-HCL, 2.5 M 
NaCl, glycerol, 0.5 M β-glycerphosphate, 
1% Tween 20, and 0.2% Nonidet P40; 
completed with EDTA-free protease inhibitor 
(Roche)]. Samples were centrifuged at maximal 
speed for 10 min, yielding the proteins in 
the supernatant.
Flow cytometry. We identified mito-
chondrial superoxide anion reactive oxygen 
species (ROS) in live cells using MitoSOX 
Red flourogenic dye (Invitrogen) according 
to the manufacturer’s guidelines. Cells were 
harvested, washed with PBS, suspended in 
250 μL of 2.5 mM Mitosox Red dissolved 
in PBS, and allowed to incubate for 20 min 
under cell culture conditions in the dark. 
Mitochondrial super oxide was measured 
by flow cytometer (FACSCalibur; BD 
Biosciences). MitoSOX Red was excited 
by laser at 488 nm and detected in the 
FL2 channel.
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After cells were harvested and washed as 
described above, mitochondrial membrane 
potential (Δψm) and apoptosis were assayed 
by incubating the cells in 80 μM 3,3´-dihexyl-
oxacarbo cyanine iodide and propidium iodide 
for 20 min at 37°C in the dark. The samples 
were then analyzed using a FACSCalibur 
flow cytometer. Cells were fixed with 70% 
ethanol and then stained with 50 μM 
propidium iodide (Sigma) for cell cycle 
analysis. Fluorescence was measured using 
the FL2 channel on a FACSCalibur flow 
cytometer. Data were analyzed using Cyflogic, 
version 1.2.1 (CyFlo Ltd.; http://www.
cyflogic.com/). 
Poly (ADP-ribose) polymerase 1 (PARP) 
cleavage. We used PARP cleavage, a hallmark 
of apoptosis (Duriez and Shah 1997), as an 
end point to identify toxicity induced by 
As2O3 exposures. PARP cleavage was evalu-
ated by Western blotting as described above. 
Transfections. We used the following 
plasmids  for  t ransfect ions :  HDAC1 
(plasmid 13820), HDAC3 (plasmid 13819), 
and HDAC4 (plasmid 13821; all from 
Addgene). HDAC2 was generously provided 
by Ito Kazuhiro (Imperial College London), 
and PCAF, HMOF, and TIP60 were kindly 
provided by Bertrand Joseph (Karolinska 
Institutet) (see Supplemental Material, 
“Plasmids”). Transient transfections were 
performed using filter-sterilized poly-
ethylenimine (PEI) reagent (Polysciences) 
at 1 mg/mL in H2O (pH 6.8). Transfection 
reagent and plasmid complex were synthesized 
using a 1:4 (wt/vol) DNA to PEI ratio made 
up to 200 μL in DMEM with no supplements 
before drop-wise addition to HEK293T cells. 
After transfection, cells were allowed to rest 
for 24 hr in fresh DMEM and then treated 
with As2O3. 
Microccocal nuclease (MNase) sensitivity 
assay. Cells were lysed in NP-40 lysis buffer, 
and nuclei were resuspended in MNase diges-
tion buffer. A total of 0.025 units of MNase 
(N3755; Sigma) was added to each sample, 
and samples were incubated for 5 min at 
15–20°C. The reaction was stopped by the 
addition of MNase digestion buffer, MNase 
stop buffer, proteinase K, and 20% SDS 
followed by overnight incubation. DNA was 
extracted by standard phenol/chloroform 
extraction and ethanol precipitation. Detailed 
methods and reagents have been described 
previously (Cold Spring Harbor Laboratory 
Press 2005).
Chromatin immunoprecipitation (ChIP). 
HEK293T and UROtsa cells were exposed to 
As2O3 for 3 or 72 hr, fixed with formaldehyde, 
and quenched with glycine. Primers used for 
ChIP are provided in Supplemental Material, 
Table S2. ChIP of samples was carried out 
as described previously (Nelson et al. 2006) 
and was followed by qRT-PCR. Enrichment 
of E2F1 in acetylated H3K9 promoters of 
TP53, BAX, PUMA, C-MYC, and C-FOS 
fragment precipitation was detected with anti-
acetylated H3K9 and anti-E2F1 antibodies. 
Ten percent of the sample was set aside as 
input. Ct values were normalized according 
to the following equation: ΔCt(normalized 
C h I P )  =  { C t( C h I P )  –  [ C t( i n p u t ) 
– log2 (0.1)]}. The percent input was calcu-
lated using the following equation: percent 
input = 2(–ΔCt[normalized ChIP]). 
Results
Identification of tolerated and toxic As2O3 
exposures. We used two cells lines in this 
study. HEK293T cells were used because they 
form a minimal number of colonies under 
anchorage-independent conditions, and they 
have good tolerance to transfection and a 
good toxicity response to As2O3. UROtsa 
cells were used because they exhibit normal 
charac teristics with no colony formation in 
soft agar and are ideal for studying environ-
mental insult to the human urothelium as 
well as bladder carcinogenesis (Rossi et al. 
2001). To ensure characterization of the 
appropriate epi genetic context, we used 
the apoptotic end point of PARP cleavage 
to identify tolerated and toxic exposures of 
As2O3 in both cell lines. PARP cleavage was 
observed from 10 μM to 80 μM As2O3 for 
cells treated for 24 hr, and for 2.5 μM As2O3 
for cells treated for 1 week for HEK293T 
cells (Figure 1A,B). Exposures of 2.5–10 μM 
As2O3 demonstrated cytotoxicity after 
1 week, as assessed by caspase-3 cleavage, 
truncation of the pro-apoptotic factor BID, 
p53 stabilization, and activation by phos-
phorylation at serine 15 (Figure 1B). No 
PARP cleavage was observed after a 1-week 
exposure to 0.5 μM As2O3, suggesting that 
this exposure was tolerated (Figure 1C). 
UROtsa cells treated for 72 hr with 1 μM 
As2O3 showed no PARP cleavage, whereas 
higher exposures of 5 μM–10 μM As2O3 
resulted in clear PARP cleavage (Figure 1D). 
This allowed us to define a tolerated exposure 
as 1 μM As2O3 and a toxic exposure as 5 μM 
As2O3 for the UROtsa cell line.
HEK293T cells treated for 72 hr with 
0.5 μM As2O3 showed no discernable differ-
ence compared with the untreated control 
group in the generation of mitochondrial 
ROS or Δψm depolarization (Figure 1E,F). 
In cells treated with 0.5 μM As2O3, cell death 
was similar to that of controls, as quantified 
by propidium iodide staining (Figure 1G). 
In contrast, treatment with 2.5 μM As2O3 
resulted in a significant increase in mito-
chondrial ROS, loss of Δψm, and cell death. 
These analyses allowed us to define tolerated 
exposure as 0.5 μM As2O3 and toxic exposure 
as 2.5 μM As2O3 in the HEK293T cell line 
for exposures ≥ 72 hr. 
Cellular proliferation, survival, and 
anchorage-independent growth in response 
to a tolerated As2O3 exposure. HEK293T 
cells exposed for 1 week to 0.5 μM As2O3 
exhibited a significantly increased elevation 
in cellular proliferation (Figure 1H). We also 
observed a significant proliferative elevation 
in UROtsa cells exposed to 1 μM As2O3 
for 72 hr or 1 week (Figure 1I). Cell cycle 
disruption was observed in both cell lines 
after 72-hr tolerated As2O3 exposure, with 
an increased percentage of cells passing the 
G1/S and G2/M checkpoints (Figure 1J,K). 
The clonogenic assay in HEK293T cells 
identified positive proliferation and cellular 
survival after treatment with 0.5 μM As2O3 
for 15 days (Figure 1L,M). A lower dose of 
0.25 μM As2O3, although tolerated, was 
unable to stimu late positive proliferation. 
Three-dimensional spheroid colonies grown 
in soft agar were larger and significantly 
increased in number in cells treated for 
12 week with 0.5 μM As2O3 compared with 
untreated control cells (Figure 1N,O). 
H3K9 and H4K12 acetylation and 
HDAC2 and PCAF mRNA expression 
profiles in response to As2O3. Two time points 
were used to identify specific arsenic-induced 
histone acetylation changes and to evaluate 
the plasticity of such events in both the 
HEK293T and UROtsa cell lines. After 3-hr 
exposure to 0.5 μM or 2.5 μM As2O3, we 
observed an elevation of H3K9 and H4K12 
acetylation in HEK293T cells (Figure 2A), 
but no change in H4K16 acetylation. In 
UROtsa cells, we observed a small, but not 
significant, increase in H3K9 and H4K16 
acetylation after a 3-hr exposure to 1 μM or 
5 μM As2O3 (Figure 2B). Significant H3K9 
hypo acetylation was observed in UROtsa 
cells after a 72-hr exposure to both tolerated 
(1 μM) and toxic (5 μM) exposures. We 
observed a similar, but not significant, trend 
in HEK293T cells, in which treatment with 
0.5 μM or 2.5 μM As2O3 resulted in hypo-
acetylation of H3K9 after 72 hr (Figure 2A). 
Transient transfection followed by 
immuno blotting identified HDAC2 and 
PCAF as the key enzymes involved in control-
ling H3K9 acetylation status (Figure 2C,D). 
Transfection with PCAF elevated H3K9 
acetyla tion relative to the control, and treat-
ment with 0.5 μM As2O3 for 3 hr synergized 
this effect with enhanced acetylation of H3K9 
(Figure 2D).
Using qRT-PCR, we measured dose-
specific expression of HDAC2. After 3 hr, 
when both As2O3 doses are tolerated, 
HDAC2  express ion was s ignif icantly 
suppressed only at the 2.5 μM dose 
(Figure 2E). In contrast, after 72 hr of 
exposure, the HDAC2 expression level was 
significantly elevated only at the tolerated 
0.5-μM As2O3 dose, leaving nominal 
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expression at 2.5 μM As2O3. Analysis of 
PCAF expression at the 3-hr time point 
revealed a significant increase in PCAF 
expression; however, at the 72-hr exposure, 
PCAF expression was suppressed at both 
tolerated and toxic doses (Figure 2F).
Effects of E2F1 binding and H3K9 
acetyla tion at selected gene promoters in 
response to As2O3. To assess the relationship 
between histone acetylation and the transcrip-
tional regulation of apoptotic genes and proto-
oncogenes, we focused on the transcription 
factor E2F1, which has been shown to influ-
ence decisions between cellular proliferation 
and cell death (Chen et al. 1985; Hallstrom 
et al. 2008). E2F1 and H3K9 acetylation 
interactions at a number of gene promoters 
including the tumor suppressor p53, apoptotic 
genes Bax and Puma, and proto-oncogenes 
Myc and Fos were assessed by the ChIP assay 
and qRT-PCR. 
HEK293T cells were exposed to As2O3 
for 3 or 72 hr. After 3 hr of exposure to 
0.5 μM As2O3, there was a significant 
enrichment of the FOS promoter fragment 
after precipitation with an anti-acetylated 
H3K9 antibody (Figure 3A). This suggests 
Figure  1. Identification of tolerated and toxic 
exposures of As2O3 (A–D) and cellular transfor‑
mation assays in HEK293T and UROtsa cell lines 
after exposure to various doses of As2O3 (E–O). 
(A–D) Representative immunoblots showing PARP 
cleavage (PARPc) after 24‑hr exposure (A); MDM2, 
p53 activation, caspase‑3 cleavage (Caspase3c), 
and apoptotic relay signals [phosphorylation 
at serine 15 (phos.ser.15), BID, and PARPc] after 
1‑week exposure (B); PARP cleavage after 1‑week 
exposure (C); and PARP cleavage (D) after 72‑hr 
exposure. (E–G) Quantification of flow cytometry 
results (presented as arbitrary units; AU) for 
mitochondrial ROS (E), mitochondrial membrane 
depolarization (ΔΨm) (F), and cell death indicated 
by propidium iodide–bound DNA (G) after 72‑hr 
exposure to 0.5 or 2.5 μM As2O3. (H,I) Quantification 
of WST‑1 proliferation assay conducted to deter‑
mine the proliferative index of HEK293T cells 
treated with 0.5 μM or 2.5 μM As2O3 (H) and UROtsa 
cells treated with 1 μM or 5 μM As2O3 (H) for 3 hr, 
72 hr, or 168 hr (1 week). (J,K) Cell‑cycle analysis 
of HEK293T cells treated with 0.5 μM or 2.5 μM 
As2O3 (J) and UROtsa cells treated with 1 μM or 
5 μM As2O3 for 72 hr, determined by propidium 
iodide staining followed by flow cytometric 
analysis. (L)  Representative images showing 
the number and approximate size of colonies of 
HEK293T cells after treatment with 0.5 μM or 2.5 μM 
As2O3 for 15 days, as determined in the clonogenic 
assay. (M) Quantification of the clonogenic assay of 
HEK293T cells after treatment with 0.5 μM or 2.5 μM 
As2O3 for 15 days; the survival fraction represents 
triplicate counting of cells. (N,O) Representative 
phase‑contrast images (10×; N) and the number of 
colonies (O) of HEK293T cells grown in soft agar 
and treated with 0.5 μM As2O3 for 12 weeks. Values 
presented are mean ± SD. 
*p < 0.05 compared with the untreated control (n = 3), 
calculated by two‑tailed Student’s t‑test. 
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an increase in H3K9 acetylation at the 
FOS promoter. Using the same duration of 
exposure and an anti-E2F1 antibody, we 
observed enrichment at the FOS promoter at 
both 0.5 μM and 2.5 μM As2O3 treatments, 
suggesting increased binding of E2F1 to the 
FOS promoter (Figure 3B). Dose-specific 
responses were observed after 72 hr exposure: 
With the use of both E2F1 and H3K9 
acetylated antibodies, significantly elevated 
binding to the FOS promoter occurred 
specifically at the tolerated 0.5-μM As2O3 
dose (Figure 3C,D). The same dose-specific 
response was validated in the UROtsa cell 
line, where 72-hr exposure to tolerated 1 μM 
As2O3 led to a significantly elevated binding 
of acetylated H3K9 and E2F1 at the FOS 
promoter fragment (Figure 3E,F).
We also examined the relative enrichment 
of PCAF and HDAC2 at the FOS promoter 
after a 72-hr exposure of HEK293T cells to 
determine whether these enzymes are involved 
in the maintenance of H3K9 acetyla tion 
(Figure 3G,H). There was increased binding 
of PCAF at the FOS promoter at the tolerated 
0.5-μM dose and at the toxic 2.5-μM As2O3 
dose. There was no significant difference in the 
HDAC2 binding at either exposure.
Effects of As2O3 on JUN, MDM2, and 
FOS expression. The effect of arsenic on the 
expression of the proto-oncogenes JUN, FOS, 
and MDM2 was measured by qRT-PCR. 
The over expression of these genes is synony-
mous with cancer stem cell expansion, p53 
regulation, and proliferation (Ito et al. 2002; 
Jiao et al. 2010).
The changes in expression observed after 
3 hr of exposure were subtle with a signifi-
cant increase only in JUN expression with the 
2.5-μM As2O3 treatment (Figure 3I). After 
72 hr of exposure, the differences were more 
pronounced between the tolerated and toxic 
exposures. This is highlighted by the expres-
sion of FOS, which was highly elevated at 
the 0.5-μM As2O3 dose. This increase was 
dose specific: There was no significant eleva-
tion in cells treated with the toxic 2.5-μM 
As2O3 dose. We observed a similar expres-
sion pattern for JUN. A significantly elevated 
expression of the FOS and JUN mRNA was 
found in the UROtsa cell line after treat-
ment with tolerated 1 μM As2O3 for 72 hr 
(Figure 3J). The expression of MDM2 
mRNA was significantly increased at the 
tolerated 0.5-μM As2O3 exposure in the 
HEK293T cell line.
Differential effects of tolerated and 
toxic As2O3 exposures on global chromatin 
conformation. We used an MNase sensitivity 
assay to assess global chromatin conforma-
tion. Rapid relaxation occurred after 3 hr 
with 0.5-μM and 2.5-μM As2O3 treatment, 
and the digestion pattern was positively 
skewed toward the 250–500 base pair size 
range, relative to the 2,000 base pair size 
(Figure 4A). Treatment with 2.5 μM As2O3 
led to greater chromatin relaxation than 
did 0.5 μM As2O3 after 3 hr. After 72 hr, 
this relaxation was reversed where the toxic 
2.5-μM As2O3 treatment led to chromatin 
condensation (Figure 4B). At 72 hr, the toler-
ated 0.5-μM As2O3 exposure has the same 
digestion pattern as the control, with the 
majority of the DNA in the 2,000 base pair–
size range, with a small elevation in the 250 
base pair range compared with the control.
Discussion
In this study we examined an in vitro 
framework to identify a tolerated dosage of 
As2O3 that induces cellular transformation 
as an important prerequisite to epigenetic 
characterization. To our knowledge, this 
initial dosage determination with knowledge 
of cellular outcome followed by the measure-
ment of epigenetic parameters is undocu-
mented. Multiple cellular transformation 
indicators ensured selection of the correct 
dosage and duration of exposure. In the 
absence of arsenic, cells showed no signs of 
deterioration or apoptosis, indicating that the 
culture conditions used were well tolerated. 
Cell line–specific tolerated and toxic dosages 
were determined. Both 0.5 μM and 2.5 μM 
As2O3 were tolerated at 3 hr in HEK293T 
cells; at 72 hr the 0.5 μM dose remained 
tolerated, but 2.5 μM As2O3 was toxic. In 
UROtsa cells, 1 μM was tolerated but 5 μM 
Figure 2. Histone acetylation analysis of HEK293T and UROtsa cells, identification of H3K9 acetylation 
control, and mRNA expression analysis of HDAC2 and PCAF in cells treated with As2O3 for 3 or 72 hr. 
(A,B) Histone acetylation (mean ± SD) of H3K9, H4K12, and H4K16 in HEK293T (A) and UROtsa (B) cells, 
analyzed by immuno blotting and densitometric analysis (see “Materials and Methods” for details). 
(C) H3K9 acetylation status analyzed by immuno blotting after transfection of HEK293T cells with a 
no‑insert control (NOI), HDAC1, HDAC2, HDAC3, or HDAC4, followed by histone extraction to examine the 
relative enzymatic effect of these HDACs on this residue; blots were quantified by densitometric analysis 
and values shown represent three independent experiments. (D) Representative immuno blot showing 
H3K9 acetylation (H3K9ac) status after transfection of HEK293T cells with a NOI or PCAF followed by a 
3‑hr exposure to 0.5 μM or 2.5 μM As2O3. (E,F) Relative mRNA expression ratios of HDAC2 (E) and PCAF (F), 
expressed as fold change for 3 and 72 hr. Values presented are mean ± SD. 
*p < 0.05 compared with the untreated control [n = 3 (B,E); n = 4 (F at 3 hr)] calculated by two‑tailed Student’s t‑test.
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As2O3 was toxic at 72 hr. Both toxic exposures 
stimulated apoptosis after a 72-hr exposure. In 
contrast, tolerated exposures were observed to 
potentiate transformative properties, including 
positive proliferation and a redistributed cell 
cycle to pass through the G1/S and G2/M 
checkpoints in both cell lines. Increased 
cellular survival and an elevated number of 
colonies grown under anchorage-independent 
conditions were observed in HEK293T cells 
after a tolerated exposure.
These findings further our understanding 
of the paradoxical effects of As2O3 as an anti-
cancer agent and carcinogen. Although it may 
be effective for some malignancies, As2O3 
treatment may not be appropriate for kidney 
and urothelial cancers, because we observed 
that tolerated exposures may lead to cellular 
transformation rather than cell death. The 
dichotomy of arsenicals as a potent cancer 
treatment and a carcinogenic compound is 
still under intense investigation. Additional 
research into these effects has attempted to 
compare and contrast the toxicity of multiple 
arsenicals. Treatment of human lung adeno-
carcinoma A549 cells with 15 μM sodium 
arsenite (NaAsO2) resulted in an increase of 
cells passing the G1/S checkpoint, in contrast 
to 15 μM As2O3, which led to a significant 
decrease, suggesting that sodium arsenite is 
potentially more carcinogenic (Jiang et al. 
2013). Doses lower than 5 μM were not a 
focus of that study, and the exposure duration 
was 24 hr, leading to toxic cellular outcomes. 
In another study, Zhou et al. (2014) 
compared the toxicity of As2O3, NaAsO2, 
and mono methyl arsonous acid (MMAIII) in 
the context of zinc finger peptides and found 
that MMAIII changed the conformation and 
displaced zinc in C2H2, C3H1, and C4 zinc 
finger proteins isolated from human kerati-
nocyte HaCaT cells. These studies demon-
strate toxicity and carcinogenicity variations 
that are dependent on the species of arsenic, 
and suggest that the dosage and duration of 
exposure are also significant, as we found in 
the present study. 
Using tolerated and toxic dosages, we 
observed temporally sensitive changes in 
global H3K9, H4K12, and H4K16 acetyla-
tion as a result of tolerated As2O3 exposure 
in both cell lines. Prior research has iden-
tified a mixture of promoter-specific and 
global histone acetylation changes. Altered 
histone H3 acetylation patterns in the DBC1, 
FAM83A ,  ZSCAN12 ,  and C1QTNF6 
gene promoters have been reported as a 
result of exposure to an intermediate of 
arsenic catabolism, MMAIII (Jensen et al. 
2008). Our observed reduction of H4K16 
acetylation, although not significant, is in 
agreement with previous research in which 
a decreasing H4K16 acetylation profile after 
chronic exposure to 3 μM As2O3 and 1 μM 
MMAIII was believed to protect cells from 
arsenic toxicity (Jo et al. 2009). Urinary 
arsenic concentration and H3K9 acetylation 
in peripheral blood mono nuclear cells are 
inversely correlated, which is concomitant 
with our observed hypo acetylation of H3K9 
at both tolerated and toxic exposures in both 
cell lines at 72 hr (Chervona et al. 2012). 
Our data suggest that hypo acetylation of 
H3K9 and H4K16 may be involved in the 
inter mediary steps toward cellular transforma-
tion. These end points alone, however, did 
not give clear mechanistic separation between 
tolerated and toxic outcomes because both 
exposures induced hypo acetylation.
We examined the association between 
hypo acetylation and cellular transformation 
by identifying the enzymes HDAC2 and 
PCAF as regulators of H3K9 acetylation in 
HEK293T cells. Subsequent investigation 
Figure 3. Tolerated As2O3 exposure induces the expression of JUN, FOS, and MDM2 and leads to the 
recruitment of E2F1 at the FOS promoter. (A–D) Chromatin immunoprecipitated with anti‑acetylated H3K9 
(H3K9ac; A,C) or anti‑E2F1 (B,D) antibodies after exposure of HEK293T cells to 0.5 μM or 2.5 μM As2O3 for 
3 or 72 hr. (E,F) Chromatin immunoprecipitated with H3K9ac (E) and anti‑E2F1 (F) antibodies after exposure 
of UROtsa cells to 1 μM or 5 μM As2O3 for 72 hr. (G,H) Chromatin immunoprecipitated with anti‑PCAF (G) 
and anti‑HDAC2 (H) antibodies for 72 hr. Precipitated chromatin was subjected to qRT‑PCR promoter 
analysis. (I) Normalized expression ratios for JUN, FOS, and MDM2 mRNA; total RNA was isolated 
from HEK293T cells treated 3 or 72 hr with 0.5 μM or 2.5 μM As2O3 treated for use in qRT‑PCR analysis. 
(J) Normalized expression ratios for JUN and FOS mRNA from UROtsa cells treated with 1 μM As2O3 for 
72 hr. Values presented are mean ± SD. 
*p < 0.05 compared with the untreated control, calculated by two‑tailed Student’s t‑test (n = 3). 
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into HDAC2 and PCAF mRNA levels by 
qRT-PCR demonstrated that the initial 
increase in global H3K9 acetylation was 
potentially caused by an adjustment in the 
HDAC2 to PCAF expression ratio. The 
direction of this imbalance was inverted at 
the 72-hr time point, where, at the toler-
ated exposure of 0.5 μM As2O3, HDAC2 
expression was significantly elevated and 
PCAF expression was significantly reduced, 
leading to global hypo acetylation of the 
H3K9 residue at the 72-hr time point in 
HEK293T cells. 
Although aberrant PCAF and HDAC2 
expression in the context of arsenic-induced 
carcinogenicity has not yet been docu-
mented, both PCAF and HDAC2 have been 
implicated in cancer. The role of PCAF is 
not definitive in carcinogenesis, but there is 
growing consensus that PCAF has tumor-
suppressive properties (Zheng et al. 2013). 
HDAC2 is also believed to interact with cell 
cycle components, where siRNA-mediated 
silencing of HDAC2 inhibits progression 
through the G1/S checkpoint in hepato-
carcinoma cells (Noh et al. 2011). This is 
particularly significant because, in our study, 
tolerated As2O3 exposure led to a redistrib-
uted cell cycle to favor cellular proliferation 
by passing both G1/S and G2/M checkpoints 
in both cell lines.
To assess the significance of global H3K9 
hypo acetylation in the transcriptional control 
of proto-oncogenes and apoptotic genes, 
we used chromatin immunoprecipitation 
to focus on the transcription factor E2F1 
because of its dual role in proliferation and 
apoptosis (Korah et al. 2012). We investi-
gated the binding of E2F1 at a number of 
promoters and identified the co-occurrence 
of promoter-specific H3K9 acetylation and 
E2F1 at the FOS promoter, a well-established 
proto-oncogene in HEK293T and UROtsa 
cells. At the 72-hr time point, this inter action 
was significantly strengthened at the toler-
ated concentration. E2F1 has been previously 
shown to interact in the promoter region of 
FOS and the retino blastoma control element 
(RCE) and regulate the transcription of 
the pRb protein, an important regulatory 
protein in balancing cellular proliferation 
and apoptosis (Mimaki et al. 2005). In the 
present study, we found that at 3 hr, H3K9 
was hyper acetylated at the FOS promoter, 
similar to the global acetylation profile. This 
localized acetylation was able to stimulate 
significant E2F1 binding at both tolerated 
and toxic exposures. This adjusted after 72 hr 
of exposure because H3K9 acetylation was 
maintained at the FOS promoter specifi-
cally at the tolerated treatment in both cell 
lines. Although global H3K9 acetylation was 
reduced at this exposure, E2F1 transcription 
factor binding was still secure at the FOS 
promoter leading to transcription. It has 
been previously documented that E2F1 is 
able to recruit other histone acetyl transferases 
such as GCN5 to acetylate localized H3K9 
residues (Guo et al. 2011). We predict that 
a potentially similar mechanism is involved 
because we identified elevated binding of 
PCAF at the FOS promoter in concert with 
E2F1 after a tolerated treatment for 72 hr. 
This allowed for the maintained H3K9 
acetylation at the promoter. Although we 
observed a similar increase in PCAF binding 
at the toxic exposure, this did not occur with 
E2F1 binding at the promoter, leaving FOS 
expression and H3K9 acetylation nominal. 
Furthermore, combined transfection with 
PCAF and treatment at the toxic dosage 
led to inhibited acetylation activity on the 
H3K9 substrate compared with transfected 
untreated controls.
Our data show how arsenic-induced 
changes in global histone acetylation may not 
always be reflected at the promoter-specific 
level. Rather, early perturbations in global 
histone acetylation may lead to transcription 
factor binding and promoter-specific effects. 
Figure 4. Tolerated and toxic As2O3 exposure alters higher‑order chromatin conformation (A,B), and 
schematic of global and promoter‑specific mechanisms in As2O3‑induced cellular transformation (C). 
(A,B) MNase sensitivity assay was used to assess the relative levels of chromatin relaxation between 
0.5 μM and 2.5 μM doses of As2O3 at 3 and 72 hr. (C) Schematic outlining HDAC2‑ and PCAF‑mediated 
global acetylation changes in H3K9 followed by subsequent E2F1 recruitment to the FOS promoter. 
Tolerated and toxic doses led to separated mechanistic outcomes after 72 hr of exposure: a toxic dose 
led to cytotoxicity and chromatin condensation, whereas tolerated exposure resulted in continued FOS 
expression. Abbreviations: H3K9ac, acetylated H3K9; Tol, tolerated dose (0.5 μM As2O3); Tox.p, toxic 
pathway (2.5 μM As2O3 at 3 hr); Tox, toxic (2.5 μM As2O3 at ≥ 72 hr). 
0.0
0.5
1.0
1.5
HEK293T, 3 hr HEK293T, 72 hr
0.0
0.5
1.0
1.5
PCAF
Tol/Tox.p
Tol
Tox.p
Tol
≥ 72 hr
C-FOS =
C-FOS 
E2F1
E2F1 =
E2F1
C-FOS =
Tox.p
H3K9ac
Tol/Tox.p
H3K9ac
Tol/Tox.p
H3K9ac
H3K9ac =
PCAF
H3K9ac
PCAF
Tol/
Tox
Tol/
Tox.p
HDAC2
Tol
Nominal chromatin conformation
Chromatin relaxation
Cellular transformation
Cytotoxicity
Chromatin condensation
and cell death
HDAC2
Tol/Tox.p
3 hr
G
lo
ba
l e
ffe
ct
s
Pr
om
ot
er
-s
pe
ci
fic
 e
ffe
ct
s
72 hr
PCAF
Tol/Tox.p
=
Increase
Decrease
No change
Control
0.5 µM As2O3
2.5 µM As2O3
Si
gn
al
 in
te
ns
ity
 (A
U)
Si
gn
al
 in
te
ns
ity
 (A
U)
7502,000≥ 10,000 500 2507502,000≥ 10,000 500 250
Base pairs Base pairs
Promoter H3K9ac in As-induced cellular transformation
Environmental Health Perspectives • volume 123 | number 5 | May 2015 491
In our proposed mechanism, arsenic exposure 
led to an adjustment in HDAC2 and PCAF 
expression and hyper acetylation of the H3K9 
residue within 3 hr (Figure 4C). This may 
allow for the early recruitment of E2F1, 
which after 72 hr resulted in PCAF-mediated 
H3K9 hyper acetylation at the promoter and 
sustained transcription. This promoter-specific 
effect occurred against a background of global 
H3K9 hypo acetylation. This understanding of 
arsenic-induced global acetylation followed by 
focused profiling at a specific gene promoter 
loci is a significant step in understanding 
arsenic-induced carcinogenesis from perturba-
tions in histone post translational status.
Transcriptional regulation and higher-
order chromatin conformation are intrinsi-
cally tethered by histone acetylation events 
that adjust the electro static properties of the 
histones (Shogren-Knaak 2006). We observed 
chromatin relaxation in a dose-dependent 
manner in addition to increases in H3K9 and 
H4K12 acetylation at the 3-hr time point in 
HEK293T cells. Extension of the exposure 
to 72 hr led to chromatin condensation 
in the toxic exposure but normalization of 
the chromatin architecture at the tolerated 
exposure in HEK293T cells. This demon-
strates the reversibility of initial relaxation, 
and this co-occurred with the global hypo-
acetylation of H3K9 and normalization of 
H412 acetylation in HEK293T cells. Similar 
condensation was observed as a result of 
As2O3-initiated apoptosis in the treatment of 
hepatocarcinoma (Alarifi et al. 2013). This 
may explain why initial E2F1 binding at 
the toxic exposure was not maintained after 
a 72-hr exposure, because the chromatin 
was severely condensed and E2F1 binding 
became unfavorable at the FOS promoter. 
We also measured the mRNA levels of other 
proto-oncogenes JUN and MDM2, both 
of which after 72 hr exhibited significantly 
elevated expression at the tolerated As2O3 
exposure, further contributing to cellular 
transformation.
Conclusions
This study provides additional mechanistic 
detail to arsenic-induced cellular transforma-
tion beginning with the analysis of histone 
post translation modifications. We believe 
that global histone acetylation changes and 
promoter-specific impacts are not entirely 
congruent and that promoter-specific histone 
acetylation changes are more accurate in sepa-
rating the opposing physiological outcomes 
of cellular transformation and toxicity. In 
summary, this research outlined a framework 
for investigating arsenic-induced carcino-
genesis by using a clear dosage selection 
methodology. Tolerated As2O3 exposure 
led to early an H3K9 acetylation increase in 
HEK293T and UROtsa cells mediated by 
an imbalance in the intra cellular HDAC2 
to PCAF expression ratio as observed in 
HEK293T cells. This event allowed for the 
subsequent binding of E2F1 at the FOS 
promoter, which maintained promoter-
localized H3K9 acetylation, against the global 
H3K9 hypo acetylation trend observed at 
the tolerated exposure in both cell lines. We 
also observed that short-term As2O3 induced 
chromatin relaxation in HEK293T cells 
and then a return to nominal levels for the 
tolerated concentration, in contrast to the 
toxic exposure, which led to clear chromatin 
condensation and apoptosis. The identifica-
tion of more promoter targets regulated by 
histone acetylation as a result of tolerated 
As2O3 exposure may help to further our 
understanding of arsenic-induced cellular 
transformation.
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